glp-1 drugs for parkinson's disease Are we measuring the wrong primary outcome for Parkinson's? Spoiler alert: the pooled data suggests we should pivot away from a motor outcome. Should we think cognitive, autonomic, sleep Glucagon-like peptide-1 (GLP-1) receptor agonists
Description
Atrium can help patients prepare by documenting BMI, weight-related conditions, prior treatment history, medication tolerance, labs, and the clinical reason a GLP-1 is being considered
TripleHormone-Receptor Agonist Retatrutide for Obesity a Phase 2 Trial
Nicholas J
Food and Drug Administration (FDA) in 2011
